NewAmsterdam Pharma Co N.V. reports
- Kastelein Johannes Jacob Pieter filed Form 4 on 2026-10-02.
- Acquired 50,246 ordinary shares on 2026-09-30.
- Sold 50,246 ordinary shares on 2026-09-30 at $25.03.
Johannes Jacob Pieter Kastelein
NAMS
NewAmsterdam Pharma Co N.V. SEC filings
Every EDGAR filing for NewAmsterdam Pharma Co N.V. (NAMS), newest first, with AI summaries and stories.
- Ticker
- NAMS
- CIK
- 1936258
- Sector
- Biotech and pharma
- Latest filing
- Oct 2
Next: earnings expected ~Nov 6 · 10-Q expected ~Nov 6 (deadline Nov 9)
Insider activity
No open-market insider buys in the last 30 days.
Also: 1 open-market sale ($1.3M), 1 grant or exercise.
Filings
Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.
ROUTINE4NewAmsterdam Pharma Co N.V.NAMSWLIVE ROUTINE8-KNewAmsterdam Pharma Co N.V.NAMSWLIVE NOTABLESCHEDULE 13D/ANewAmsterdam Pharma Co N.V.NAMSWLIVE Ownership stake disclosure by Frazier Life Sciences X, L.P. (amended)
Frazier Life Sciences X, L.P., filed by
ROUTINE8-KNewAmsterdam Pharma Co N.V.NAMSWLIVE ROUTINE4NewAmsterdam Pharma Co N.V.NAMSWLIVE Michael H. Davidson, insider filing for NAMSW
Michael H. Davidson, reporting
ROUTINE4NewAmsterdam Pharma Co N.V.NAMSWLIVE John W Smither, insider filing for NAMSW
John W Smither, reporting
ROUTINE4NewAmsterdam Pharma Co N.V.NAMSWLIVE Robert William Gunning, insider filing for NAMSW
Robert William Gunning, reporting
ROUTINE144/ANewAmsterdam Pharma Co N.V.NAMSWLIVE Johannes Jacob Pieter Kastelein, planned sale of NAMSW shares (amended)
Johannes Jacob Pieter Kastelein, reporting
ROUTINE4NewAmsterdam Pharma Co N.V.NAMSWLIVE Johannes Jacob Pieter Kastelein, insider filing for NAMSW
Johannes Jacob Pieter Kastelein, reporting
ROUTINE144NewAmsterdam Pharma Co N.V.NAMSWLIVE Johannes Jacob Pieter Kastelein, planned sale of NAMSW shares
Johannes Jacob Pieter Kastelein, reporting
ROUTINE8-K/ANewAmsterdam Pharma Co N.V.NAMSWLIVE ROUTINE3NewAmsterdam Pharma Co N.V.NAMSWLIVE Robert William Gunning, new insider at NAMSW
Robert William Gunning, reporting
ROUTINE8-KNewAmsterdam Pharma Co N.V.NAMSWLIVE ROUTINESCHEDULE 13G/ANewAmsterdam Pharma Co N.V.NAMSWLIVE Ownership stake disclosure by FMR LLC (amended)
FMR LLC, filed by
ROUTINE8-KNewAmsterdam Pharma Co N.V.NAMSWLIVE NOTABLE10-QNewAmsterdam Pharma Co N.V.NAMSWLIVE ROUTINE8-KNewAmsterdam Pharma Co N.V.NAMSWLIVE ROUTINE4NewAmsterdam Pharma Co N.V.NAMSWLIVE Louise Frederika Kooij, insider filing for NAMSW
Louise Frederika Kooij, reporting
ROUTINE8-KNewAmsterdam Pharma Co N.V.NAMSWLIVE ROUTINE4NewAmsterdam Pharma Co N.V.NAMSWLIVE Louise Frederika Kooij, insider filing for NAMSW
Louise Frederika Kooij, reporting
ROUTINES-8NewAmsterdam Pharma Co N.V.NAMSWLIVE ROUTINESCHEDULE 13G/ANewAmsterdam Pharma Co N.V.NAMSWLIVE Ownership stake disclosure by Capital World Investors (amended)
Capital World Investors, filed by
ROUTINE8-KNewAmsterdam Pharma Co N.V.NAMSWLIVE ROUTINE4NewAmsterdam Pharma Co N.V.NAMSWLIVE Louise Frederika Kooij, insider filing for NAMSW
Louise Frederika Kooij, reporting
ROUTINE144NewAmsterdam Pharma Co N.V.NAMSWLIVE Louise Frederika Kooij, planned sale of NAMSW shares
Louise Frederika Kooij, reporting
NOTABLESCHEDULE 13D/ANewAmsterdam Pharma Co N.V.NAMSWLIVE Ownership stake disclosure by BCLS II Investco, LP (amended)
BCLS II Investco, LP, filed by
ROUTINE8-KNewAmsterdam Pharma Co N.V.NAMSWLIVE NOTABLE10-QNewAmsterdam Pharma Co N.V.NAMSWLIVE ROUTINESCHEDULE 13G/ANewAmsterdam Pharma Co N.V.NAMSWLIVE Ownership stake disclosure by FMR LLC (amended)
FMR LLC, filed by
ROUTINEARSNewAmsterdam Pharma Co N.V.NAMSWLIVE ROUTINEDEF 14ANewAmsterdam Pharma Co N.V.NAMSWLIVE ROUTINE8-KNewAmsterdam Pharma Co N.V.NAMSWLIVE ROUTINEPRE 14ANewAmsterdam Pharma Co N.V.NAMSWLIVE ROUTINE4NewAmsterdam Pharma Co N.V.NAMSWLIVE Louis G Lange, insider filing for NAMSW
Louis G Lange, reporting
ROUTINE144NewAmsterdam Pharma Co N.V.NAMSWLIVE Louis G Lange, planned sale of NAMSW shares
Louis G Lange, reporting
ROUTINE4NewAmsterdam Pharma Co N.V.NAMSWLIVE Louis G Lange, insider filing for NAMSW
Louis G Lange, reporting
ROUTINE4NewAmsterdam Pharma Co N.V.NAMSWLIVE Johannes Jacob Pieter Kastelein, insider filing for NAMSW
Johannes Jacob Pieter Kastelein, reporting
ROUTINE144NewAmsterdam Pharma Co N.V.NAMSWLIVE Louis G Lange, planned sale of NAMSW shares
Louis G Lange, reporting
ROUTINE144NewAmsterdam Pharma Co N.V.NAMSWLIVE Johannes Jacob Pieter Kastelein, planned sale of NAMSW shares
Johannes Jacob Pieter Kastelein, reporting
ROUTINE4NewAmsterdam Pharma Co N.V.NAMSWLIVE Michael H. Davidson, insider filing for NAMSW
Michael H. Davidson, reporting
ROUTINE144NewAmsterdam Pharma Co N.V.NAMSWLIVE Michael H. Davidson, planned sale of NAMSW shares
Michael H. Davidson, reporting
ROUTINE8-KNewAmsterdam Pharma Co N.V.NAMSWLIVE ROUTINE4NewAmsterdam Pharma Co N.V.NAMSWLIVE Michael H. Davidson, insider filing for NAMSW
Michael H. Davidson, reporting
ROUTINE4NewAmsterdam Pharma Co N.V.NAMSWLIVE Johannes Jacob Pieter Kastelein, insider filing for NAMSW
Johannes Jacob Pieter Kastelein, reporting
ROUTINE144NewAmsterdam Pharma Co N.V.NAMSWLIVE Michael H. Davidson, planned sale of NAMSW shares
Michael H. Davidson, reporting
ROUTINE144NewAmsterdam Pharma Co N.V.NAMSWLIVE Johannes Jacob Pieter Kastelein, planned sale of NAMSW shares
Johannes Jacob Pieter Kastelein, reporting
ROUTINES-8NewAmsterdam Pharma Co N.V.NAMSWLIVE NOTABLE10-KNewAmsterdam Pharma Co N.V.NAMSWLIVE ROUTINE8-KNewAmsterdam Pharma Co N.V.NAMSWLIVE ROUTINESCHEDULE 13G/ANewAmsterdam Pharma Co N.V.NAMSWLIVE Ownership stake disclosure by VIKING GLOBAL INVESTORS LP (amended)
VIKING GLOBAL INVESTORS LP, filed by